Q3 EPS Forecast for Lyra Therapeutics Reduced by Analyst

Lyra Therapeutics, Inc. (NASDAQ:LYRA) – Stock analysts at William Blair reduced their Q3 2025 earnings per share estimates for Lyra Therapeutics in a report issued on Monday, January 20th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($0.12) per share for the quarter, down from their prior estimate of ($0.11). The consensus estimate for Lyra Therapeutics’ current full-year earnings is ($0.93) per share. William Blair also issued estimates for Lyra Therapeutics’ Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.52) EPS.

Lyra Therapeutics Price Performance

LYRA opened at $0.19 on Wednesday. The company has a market capitalization of $12.61 million, a price-to-earnings ratio of -0.13 and a beta of -0.13. The business’s 50-day moving average price is $0.19 and its two-hundred day moving average price is $0.25. Lyra Therapeutics has a 1 year low of $0.16 and a 1 year high of $6.79.

Institutional Trading of Lyra Therapeutics

An institutional investor recently raised its position in Lyra Therapeutics stock. State Street Corp grew its position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) by 88.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 488,720 shares of the company’s stock after acquiring an additional 228,900 shares during the period. State Street Corp owned about 0.75% of Lyra Therapeutics worth $126,000 at the end of the most recent quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Lyra Therapeutics

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.